Expression of ADAMTS-1, ADAMTS-4, ADAMTS-5 and TIMP3 by hepatocellular carcinoma cell lines

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 1043-1049

  Turner, Sharon L ^a   Mangnall, David ^b   Bird, Nigel C ^b   Bunning, Rowena A D ^a   Blair Zajdel, Maria E ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

A disintegrin and metalloproteinase with thrombo spondin motifs (ADAMTS) 1, 4, 5; Cytokines; Liver cancer; Tissue inhibitors of metalloproteases 3

Indexed keywords

ADAMTS1 PROTEIN; AGGRECANASE 1; AGGRECANASE 2; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CELL STRAIN HEPG2; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADAM PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; HEP G2 CELLS; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIVER; LIVER NEOPLASMS; PROCOLLAGEN N-ENDOPEPTIDASE; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865035645     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1525     Document Type: Article

References (33)

1. Wilson JF: Liver cancer on the rise. Ann Intern Med 142: 1029-1032, 2005.
2. Merle P and Trepo C: Molecular mechanisms underlying hepatocellular carcinoma. Viruses 1: 852-872, 2009.
3. Giannelli G and Antonaci S: Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J Clin Gastroenterol 40: 842-846, 2006. (Pubitemid 44506930)
4. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
5. Price JT and Thompson EW: Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin Ther Targets 6: 217-233, 2002. (Pubitemid 34477462)
6. Porter S, Clark IM, Kevorkian L and Edwards DR: The ADAMTS metalloproteinases. Biochem J 386: 15-27, 2005.
7. Kashiwagi M, Enghild JJ, Gendron C, Hughes C, Caterson B and Itoh Y: Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J Biol Chem 279: 10109-10119, 2004. (Pubitemid 38372615)
8. Bandtlow CE and Zimmermann DR: Proteoglycans in the developing brain: new conceptual insights for old proteins. Physiol Rev 80: 1267-1290, 2000.
9. Luque A, Carpizo DR and Iruela-Arispe ML: ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem 278: 23656-23665, 2003. (Pubitemid 36830188)
10. Hsu Y-P, Staton CA, Cross N and Buttle DJ: Anti-angiogenic properties of ADAMTS-4 in vitro. Int J Exp Pathol 93: 70-77, 2012.
11. Sharghi-Namini S, Fan HP, Sulochana KN, Potturi P, Xiang W, Chong YS, Wang ZY, Wang H and Ge RW: The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor. Biochem Biophys Res Commun 371: 215-219, 2008.
12. Kuno K, Bannai K, Hakozaki M, Matsushima K and Hirose K: The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. Biochem Biophys Res Commun 319: 1327-1333, 2004. (Pubitemid 38759556)
13. Held-Feindt J, Paredes EB, Blömer U, Seidenbecher C, Stark AM, Mehdorn HM and Mentlein R: Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas. Int J Cancer 118: 55-61, 2006. (Pubitemid 41681580)
14. Nagase H, Visse R and Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69: 562-573, 2006. (Pubitemid 43139720)
15. Lambert E, Dassé E, Haye B and Petitfrère E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol 49: 187-198, 2004. (Pubitemid 38251351)
16. Bugno M, Witek B, Bereta J, Bereta M, Edwards DR and Kordula T: Reprogramming of TIMP-1 and TIMP-3 expression profiles in brain microvascular endothelial cells and astrocytes in response to proinflammatory cytokines. FEBS Lett 448: 9-14, 1999. (Pubitemid 29151620)
17. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4: Nature 227: 680-685, 1970.
18. Haddock G, Cross AK, Plum J, Surr J, Buttle DJ, Bunning RAD and Woodroofe NM: Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter. Mult Scler 12: 386-396, 2006. (Pubitemid 44132579)
19. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal genes. Genome Biol 3: Research 0034, 2002.
20. Pfaffl MW: A new mathematical model for relative quantifi- cation in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
21. Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, Sakamoto K and Ikari T: Pathology of hepatocellular carcinoma in Japan. 232 consecutive cases autopsied in ten years. Cancer 51: 863-877, 1983. (Pubitemid 13143165)
22. Illemann M, Bird NC, Majeed A, Lærum OD, Lund LR, Danø K and Nielsen BS: Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 124: 1860-1870, 2009.
23. Jones GC and Riley GP: ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res Ther 7: 160-169, 2005. (Pubitemid 40936607)
24. Liu YJ, Xu Y and Yu Q: Full-length ADAMTS-1 and ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 25: 2452-2467, 2006.
25. Seals DF and Courtneidge SA: The ADAMs family of metalloprotease: Multidomain proteins with multiple functions. Genes Dev 17: 7-30, 2003. (Pubitemid 36062504)
26. Hu B, Kong LL, Matthews RT and Viapiano MS: The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility. J Biol Chem 283: 24848-24859, 2008.
27. Darnton SJ, Hardie LJ, Muc RS, Wild CP and Casson AG: Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: Loss of expression correlates with poor prognosis. Int J Cancer 115: 351-358, 2005. (Pubitemid 40663737)
28. Hashimoto G, Shimoda M and Okada Y: ADAMTS-4 (aggrecanase-1) interaction with the C-terminal domain of fibronectin inhibits proteolysis of aggrecan. J Biol Chem 279: 32483-32491, 2004. (Pubitemid 39014703)
29. Miyazaki T, Kato H, Nakajima M, Faried A, Takita J, Sohda M, Fukai Y, Yamaguchi S, Masuda N, Manda R, Fukuchi M, Ojima H, Tsukada K and Kuwano H: An immunohistochemical study of TIMP-3 expression in oesophageal squamous cell carcinoma. Br J Cancer 91: 1556-1560, 2004. (Pubitemid 39486362)
30. Ryder SD: Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 52: iii1-iii8, 2003.
31. Berasain C, Castillo J, Prieto J and Avila MA: New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 153: 174-185, 2007. (Pubitemid 46680720)
32. Zimmers TA, McKillop IH, Pierce RH, Yoo J and Koniaris LG: Massive liver growth in mice induced by systemic interleukin 6 administration. Hepatology 38: 326-334, 2003. (Pubitemid 36919853)
33. Masui T, Hosotani R, Tsuji S, Miyamtot Y, Yasuda S, Ida J, Nakajima S, Kawaguchi M, Koybayashi H, Koizuma M, Toyoda E, Tulachan S, Arii S, Doi R and Imamura M: Expression of METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res 7: 3437-3443, 2001. (Pubitemid 33069978)